Overview

• Med tech firm's fiscal Q2 net sales beat analysts' expectations, driven by Med Tech growth

• Adjusted net income for fiscal Q2 beat estimates

• Company achieved FDA approvals for Mechanical Thrombectomy portfolio

• Company raised FY 2026 guidance for net sales and adjusted EBITDA

Outlook

• AngioDynamics raises FY 2026 net sales guidance to $312 - $314 mln

• Company expects FY 2026 adjusted EBITDA between $8.0 mln and $10.0 mln

• AngioDynamics maintains positive cash flow guidance for FY 2026

Result Drivers

• MED TECH GROWTH - Med Tech segment saw a 13% increase in net sales, driven by platforms like Auryon and NanoKnife

• REGULATORY MILESTONES - Achieved FDA approvals for APEX-Return study and PAVE clinical study, expanding Mechanical Thrombectomy portfolio

• GROSS MARGIN IMPROVEMENT - Gross margin increased due to product mix shift towards Med Tech and manufacturing initiatives

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for AngioDynamics Inc is $17.00, about 28.5% above its January 5 closing price of $13.23

Press Release: ID:nBw3MhKHpa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)